Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation - intersubject variability in systemic absorption from the lung
C. Minto et al., Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation - intersubject variability in systemic absorption from the lung, BR J CL PH, 50(2), 2000, pp. 116-124
Aims Pharmacokinetic variability is likely to be a significant factor contr
ibuting to the interindividual differences in dose requirements anti-inflam
matory response and side-effects with inhaled corticosteroids (ICS), but th
ere is limited information about the disposition of ICS during regular dosi
ng with a pressurized metered dose inhaler (pMDI). This study uses a mixed
effects modelling approach to quantify and compare the interindividual vari
ability in pharmacokinetics of epimeric budesonide (BUD) and fluticasone pr
opionate (FP) after repeat-dose inhalation.
Methods This pharmacokinetic substudy was part of a previously published op
en-label, randomised, placebo-controlled, 7-period crossover study to evalu
ate the short-term effects on plasma cortisol levels of inhaled BUD (400, 8
00, 1600 mu g twice daily) and FP (375, 750, 1000 mu g twice daily) via pMD
I in a group of healthy male volunteers. On the fifth day of each high-dose
treatment period (BUD 1600 mu g twice daily and FP 1000 mu g twice daily),
venous blood samples were collected in nine subjects Frier to the last dos
e and at 15 min, 30 min, 1, 2, 4, 6 and 8 h postdose for measurement of pla
sma drug concentrations to determine the pharmacokinetics of epimeric BUD a
nd FP following inhalation. Non-compartmental analysis and a mixed effects
model were used to characterize the disposition profiles.
Results Both drugs had a rapid absorption half-life (BUD 10 min vs FP 11.3
min), but quite dint rent elimination half-lives (BUD 2.4 h vs FP 7.8 h). A
lthough there were intraindividual differences in the handling of the 22R-a
nd 22S-epimers of BUD, then were no consistent pharmacokinetic differences
between the two enantiomers ill the group as a whole. Consistent with previ
ous reports of FP's higher volume of distribution (V) and lower systemic bi
oavailability (F), the V/F ratio was lower for BUD than FP (498 1 vs 8100 1
). The parameter with the greatest interindividual variability for both BUD
and FD was the rate of systemic absorption from the lung.
Conclusions This is the first report describing the pharmacokinetics of epi
meric BUD and FP after repeat dose inhalation via pMDI. Three observations
may be of clinical relevance: (1) there is considerable intersubject variab
ility in the rate of absorption of both drugs from the lung; (2) in some in
dividuals there was a long t(1/2,z), for BUD, resulting in higher and more
sustained plasma drug levels in the 4-12 h postdose period than would be pr
edicted from single-dose pharmacokinetic data; and (3) there is evidence of
diurnal variation in FP pharmacokinetics, with higher-than-expected plasma
drug concentrations in the morning compared with the evening.